ABSTRACT
In the current mini-review, we present a short overview of genetic as well as immunohistochemical p14 ARF alterations either in primary human endometrial carcinomas (ECs) or in metastatic lesions originated from malignant endometrium. The prognostic utility of p14 ARF in uterine malignancies has also been briefly discussed.
INTRODUCTION
The INK4B-INK4A locus, located on human chromosome 9p21, encoded two cyclin-dependent kinase inhibitors, p15
INK4b and p16
INK4A
, and an un-related protein encoded ARF (known as p14 ARF in human and p19 ARF in mouse; Figure 1 ) (1, 2, 3) . Interestingly, mouse and human proteins differs in amino-acid sequences and are composed of 169 and 132 amino acids, respectively (1, 4) . They are 
. p14 ARF protein acts through the p53-pathway, interacting with the MDM2 protein. MDM2 stabilized p53, resulting in arrest of the cell cycle at the G1/G2 phases. both composed of more than 20% arginine residues conferring them highly basic and hydrophobic properties (4). Nuclear p14 ARF consists of 132 amino acids and mediates cell-cycle arrest at G1 and G2/M phases by interfering with p53/MDM2 (4, 5) . It is well-known that alterations at CDKN2A locus represent a convergence of two major cell-cycle regulatory pathways involved in human tumorigenesis: the TP53-pathway and the pRbpathway (5, 6) . Indeed, deletion at the ARF-INK4a simultaneously impairs not only INK4A-cyclin D/CKD4/6-Rb but also ARF-MDM2-p53 pathways (7). p14 ARF induced an increase in MDM2 (a member of the pRbpathway) and p21
, resulting to cell-cycle arrest not only at G1 but also at G2/M phases (1, 9) . Moreover, p14 ARF in negatively regulated by p53, and it is known to bind directly to MDM2 (1, 5, 9 ).
In the current mini-review, we discuss the role of p14 ARF alterations during endometrial carcinogenesis as well as the immunohistochemical protein expression in primary and metastatic human ECs (Endometrial Carcinomas). Finally, the prognostic utility of p14 ARF in uterine malignancies has also been briefly discussed.
p14

ARF
ALTERATIONS IN ENDOMETRIAL CARCINOGENESIS
Alterations of p53-pathway members, including p14 ARF , has been reported to be one of the most important mechanism in the development of various human malignancies (4, 10, 11, 12, 13, 14, 15, 16, 17) , including tumors developing from the female genital tract organs (18, 19, 20, 21, 22) . Interestingly, mutations at p14 ARF , specifically splice-site variants, are causal in a subset of melanoma patients independently of p16 INK4A (23) . On the other hand, no relationship between bladder cancer recurrence and p14 ARF methylation was previously reported (24) .
In human uterine malignancies, Tsuda and coinvestigators (19) described a homozygous deletion at the CDKN2 with subsequent loss of p16
INK4a and p14
ARF
. At this locus, point mutations and allelic imbalance were rarely identified (25). Ozenne and co-workers (4) stated that "…germline mutations affecting specifically exon 1β
have not yet been identified, and mutations that specifically target exon 1β are rare in human tumors". Moreover, there were no mutations detected in the three exons of the CDKN2 by Koul and co-workers (26). Recently, no point mutations at the p14 ARF were described (20) . These authors suggested that PCR-SSCP analysis, applied in their research, may not detect every genetic distortions in ECs. As reported in the literature, the sensitivity of this technique to detect gene alterations (point mutations and/or homozygous deletions) has been shown to be extremely high (up to 90%!) (27, 28, 29). Other mechanisms apart from point mutation, homozygous deletions or CpG promoter methylation, for example RNA spicing errors, may also be implicated in gene distortions (20) .
Esteller and co-investigators (30) previously found p14 ARF promoter methylation in 15% of endometrial tumors evaluated. Promoter methylation was no detected in any normal tissue, including human endometrial tissue ARF expression in primary human ECs (p=0.302; log-rank test).
(30). Finally, they suggested that "…..after a screening of more than 500 primary human tumors of different cell types, p14 ARF promoter hypermethylation was found as a relatively common event in several neoplasms, including colorectal, gastric, and uterine tumors" (30). In another study, three out of 50 (6%) carcinomas showed methylation in the 5'CpG island in the promoter region of the gene (20) . None of the five p14
INK4A
-negative carcinomas revealed promoter methylation. As suggested by Watanabe and coinvestigators (31), p14 ARF promoter methylation might be a late event during endometrial carcinogenesis due to the fact that lack of p14 ARF immunoreactivity was reported at high rate in poorly-differentiated endometrioid-type ECs.
p14 ARF IMMUNOSTAINING IN NORMAL, PRECANCEROUS AND CANCEROUS HUMAN ENDOMETRIAL TISSUES
There is a limited number of studies analyzing p14 ARF immunoreactivity in normal, precancerous and cancerous human endometrial tissues up to now (20, 31, 32, 33, 34) . Nuclear p14 ARF immunostaining was detected in the ten normal endometrial slides whereas only in 5 out of 64 (7,8%) endometrioid-type ECs revealed abnormal protein immunoreactivity (20) . No significant differences between p14
ARF expression pattern and clinical stage or histological grade was reported (20) . In the largest cohort published up to now, Watanabe and co-investigators (31) showed positive p14 ARF immunoreactivity in 55%, 60%, and 62,1% of normal, hyperplasic and neoplastic human endometrial slides, respectively. The frequency of p14 ARF immunoreactivity was inversely correlated with the histological grade (G1 versus G3, p=0.0159). Moreover, the staining score was significantly higher in endometrioidtype ECs than in endometrial hyperplasias (p<0.05); whereas p14 ARF in uterine tumors was correlated inversely with the labeling index of Ki-67, but not with cell-cycle regulators studies (cyclins A, D1 and E, cdk2, p27 or p53). Finally, the authors concluded that "high expression of p14 ARF is induced in endometrial adenocarcinomas, especially in G1 tumors, in which E2F-1 might be overexpressed" (31). Interestingly, none of 8 primary squamous cell carcinomas of the endometrium revealed p14 It has been previously proposed that endometrial carcinoma cells, uterine-papillary serous carcinoma (UPSC) in particular, may exfoliate, transverse the tube lumen, and finally implant into the peritoneum (35, 36, 37). Snyder and co-investigators (37) suggested that "… aberrant cell-cell adhesion secondary to a mutation in an adhesion molecule gene that results in the overexpression of a defective protein or lack of expression of that protein altogether causes less cell to cell adhesion." Various molecules, including E-cadherin, p120 and/or CD44, may influence of endometrial cancer cells to behave clinically aggressive (38, 39, 40, 41). This mechanism may be occasionally related to early-stage uterine tumors, only superficially infiltrated the myometrial wall (37). Retrograde transtubal implantation, an under-recognized mechanism of uterine cancer metastasis, as well as lymphatic/vascular space invasion (LV), are two major postulated routs of neoplasmatic dissemination. Alterations at p14 ARF as well as aberrant protein immunoreactivity may also be involved in this process (34) but further studies are required to determine the exact role of p14 ARF in ability of ECs to transtubal route of spread.
p14 ARF AND PATIENTS OUTCOME
In the literature, Kawamoto and co-workers (42) showed a significantly poorer outcome of patients affected by human bladder cancer with p14 ARF promoter methylation that those without. They assumed that p14 ARF may be a useful biomarker for the pathological stage and outcome of patients affected by bladder carcinomas (42).
Simultaneous hypermethylation of both p16
INK4a and p14 ARF was greater prognostic value in patients affected by sporadic human colorectal cancer (43). p14 ARF immunoreactivity index constituted independent predictive factor for recurrence of urothelial neoplasms of the human bladder (24) , and in myxoid/round cell liposarcomas (44).
Various genetic and immunohistochemical markers were evaluated as perspectives molecular tools in early-and advanced-stage uterine malignancies (45, 46, 47, 48, 49, 50, 51, 52, 53, 54) . Members of the p53-pathway, p53 and MDM2, were reported to be implicated as poor prognosticators of patients affected by ECs (55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65) . However, up to now only one study evaluated the impact of p14 ARF expression as a prognostic tool in advanced-stage ECs (34). p14 ARF expression/overexpression pattern was not related to unfavorable outcome of women, either in primary ECs (p=0.302; Figure 2 ) or in corresponding metastatic lesions (p=0.217; Figure 3) . As a conclusion, this marker should not be used as a prognosticator in women suffered from advanced-stage uterine malignancies (34). Further study is required to assess the prognostic utility of p14 ARF expression pattern/genetic alterations in early-staged ECs or even precancerous lesions of human endometrium.
FUTURE PERSPECTIVES
p14ARF
alterations, especially promoter (hyper)methylation, may influence on the development and progression of various endometrial malignancies. In the future perspectives, the relation between p14ARF, MDM2 and p53 should be carefully overlapped, particularly in early-staged ECs. Indeed, influence of aberrant p14ARF promoter methylation on outcome of women affected by early/advanced-ECs should also be evaluated in multi-center, cohort research.
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